Loading
Cansera
Cansera is a Los Angeles start-up writing software that searches images of a blood sample for the very rare cells, such as tumour cells, that can signal cancer. Its tool, CellLogic, is funded by the US National Cancer Institute.
Also called: Cansera, Inc.
Overview
Cansera, Inc. describes itself as an AI-driven biotechnology start-up that unlocks digital biomarkers from routine blood tests, analysing whole fluorescent slide images of blood without preselecting what to look for, so that rare circulating cells can be found at scale rather than by manual review. In 2026 it received a National Cancer Institute STTR award to develop CellLogic, which, according to the award abstract, uses an unsupervised deep-learning model to flag candidate rare-cell regions in fluorescent whole slide images and a downstream module to characterise single cells.
Headquarters
Los Angeles, CA, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI STTR (R42) award 1R42CA314789-01: CellLogic: Deep Learning Identification and Characterization of Rare Events in Fluorescent Whole Slide Imaging | 2026 | $291K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
- Company website and the NIH RePORTER record read on 4 November 2026. Founding year not stated on the website.
Connected
3fronts
technologies
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
cansera.com · 1
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/